Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR
Graphical abstract
Section snippets
Acknowledgment
Thanks to Steve Swann for assistance in preparing this manuscript.
References and notes (9)
- et al.
Cell
(2000) - et al.
Anal. Biochem.
(2002) - et al.
Bioorg. Med. Chem. Lett.
(2009) - et al.
Cancer Res.
(2008)
Cited by (62)
Therapeutic advancements in targeting BCL-2 family proteins by epigenetic regulators, natural, and synthetic agents in cancer
2023, European Journal of PharmacologyApplications of “linkers” in fragment-based drug design
2022, Bioorganic ChemistryCitation Excerpt :And when the hydrophobic substituent was added back to the core of the diphenylmethane in the linker compound, the most potent compound 21 was obtained by modification, and the Kd value could reach 40 nM. Thus this linker moiety could provide a useful starting point for the development of effective Bcl-2 selective antitumor drugs [38]. To find new LDH-A inhibitors, Kohlmann et al. used a fragment-based approach to identify low-molecular-weight compounds-oxaline, which binds to LDH-A, and introduced flexible linkers of seven to nine atoms to connect the space between the two oxaline variant molecules.
Discovery of novel biaryl sulfonamide based Mcl-1 inhibitors
2019, Bioorganic and Medicinal Chemistry LettersPotent and Selective EphA4 Agonists for the Treatment of ALS
2017, Cell Chemical BiologyCitation Excerpt :Based on these observations, we used an innovative approach to drug discovery, termed HTS by NMR, that takes advantage of modern fragment-based drug discovery principles, combinatorial chemistry, and NMR-based screening to identify novel initial hit molecules and characterize their binding mode on the surface of the target (Barile and Pellecchia, 2014; Bottini et al., 2015; Wu et al., 2013, 2015a). Here, instead of testing by NMR mixtures of possible fragments and subsequently synthesizing bidentate agents after pairs of ligands have been discovered (Becattini and Pellecchia, 2006; Chen et al., 2007; Petros et al., 2010; Shuker et al., 1996), we combine the fragments directly into a common scaffold and test by NMR the pre-assembled molecules in mixtures gathered in positional scanning fashion (Wu et al., 2013, 2015a). These studies led to the identification of the initial hit molecule compound 22 (Table 1) that was able to bind selectively to the EphA4-LBD in the mid-micromolar range.
Fragment-Based Drug Design by NMR
2017, Encyclopedia of Spectroscopy and SpectrometrySelective inhibitors of Bcl-2 and Bcl-x<inf>L</inf>: Balancing antitumor activity with on-target toxicity
2016, Bioorganic and Medicinal Chemistry Letters